Utility of response evaluation to neo-adjuvant chemotherapy by 18F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma

Surgery

Volumn 148, Issue 5, 2010, Pages 908-918

  Makino, Tomoki ^a   Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Fujiwara, Yoshiyuki ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Higuchi, Ichiro ^c   Hatazawa, Jun ^b   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Iseikai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; DIAGNOSTIC USE; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES;

AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77958085965     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2010.02.016     Document Type: Article

References (56)

1. Medical Research Council Oesophageal Cancer Working Group Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial Lancet 359 2002 1727 1733
2. N. Ando, T. Iizuka, T. Kakegawa, K. Isono, H. Watanabe, and H. Ide A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study J Thorac Cardiovasc Surg 114 1997 205 209
3. K. Isono, H. Sato, and K. Nakayama Results of a nationwide study on the three-field lymph node dissection of esophageal cancer Oncology 48 1991 411 420
4. H. Akiyama, M. Tsurumaru, H. Udagawa, and Y. Kajiyama Radical lymph node dissection for cancer of the thoracic esophagus Ann Surg 220 1994 364 372
5. Y. Tabira, N. Kitamura, M. Yoshioka, M. Tanaka, K. Nakano, and N. Toyota Significance of three-field lymphadenectomy for carcinoma of the thoracic esophagus based on depth of tumor infiltration, lymph nodal involvement and survival rate J Cardiovasc Surg (Torino) 40 1999 737 740
6. V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, and J. Simes Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis Lancet Oncol 8 2007 226 234
7. J.D. Urschel, and H. Vasan A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer Am J Surg 185 2003 538 543
8. F. Fiorica, D. Di Bona, F. Schepis, A. Licata, L. Shahied, and A. Venturi Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis Gut 53 2004 925 930
9. N. Ando, T. Iizuka, H. Ide, K. Ishida, M. Shinoda, and T. Nishimaki Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204 J Clin Oncol 21 2003 4592 4596
10. I.G. Kaklamanos, G.R. Walker, K. Ferry, D. Franceschi, and A.S. Livingstone Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials Ann Surg Oncol 10 2003 754 761
11. D. Cunningham, W.H. Allum, S.P. Stenning, J.N. Thompson, C.J. Van de Velde, and M. Nicolson MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
12. A.R. Padhani, and L. Ollivier The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists Br J Radiol 74 2001 983 986
13. Japanese Society of Esophageal Diseases. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 10th ed. Tokyo, Japan: Kanehara & Co., Ltd., 2007.
14. J. Matsuyama, Y. Doki, T. Yasuda, H. Miyata, Y. Fujiwara, and S. Takiguchi The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus Surgery 141 2007 570 580
15. H. Kato, H. Kuwano, M. Nakajima, T. Miyazaki, M. Yoshikawa, and H. Ojima Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma Cancer 94 2002 921 928
16. Y.C. Yoon, K.S. Lee, Y.M. Shim, B.T. Kim, K. Kim, and T.S. Kim Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study Radiology 227 2003 764 770
17. E.P. van Vliet, M.H. Heijenbrok-Kal, M.G. Hunink, E.J. Kuipers, and P.D. Siersema Staging investigations for oesophageal cancer: a meta-analysis Br J Cancer 98 2008 547 557
18. B.L. Brucher, W. Weber, M. Bauer, U. Fink, N. Avril, and H.J. Stein Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography Ann Surg 233 2001 300 309 (Pubitemid 32187807)
19. R.J. Downey, T. Akhurst, D. Ilson, R. Ginsberg, M.S. Bains, and M. Gonen Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial J Clin Oncol 21 2003 428 432
20. W.A. Weber, K. Ott, K. Becker, H.J. Dittler, H. Helmberger, and N.E. Avril Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
21. P. Flamen, E. Van Cutsem, A. Lerut, J.P. Cambier, K. Haustermans, and G. Bormans Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer Ann Oncol 13 2002 361 368
22. J. Duch, D. Fuster, M. Muñoz, P.L. Fernández, P. Paredes, and M. Fontanillas (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer Eur J Nucl Med Mol Imaging 36 2009 1551 1557
23. A. Kumar, R. Kumar, V. Seenu, S.D. Gupta, M. Chawla, and A. Malhotra The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol 19 2009 1347 1357
24. K. Hamada, Y. Tomita, A. Inoue, T. Fujimoto, N. Hashimoto, and A. Myoui Evaluation of chemotherapy response in osteosarcoma with FDG-PET Ann Nucl Med 23 2009 89 95
25. M.R. Benz, M.S. Allen-Auerbach, F.C. Eilber, H.J. Chen, S. Dry, and M.E. Phelps Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas J Nucl Med 49 2008 1579 1584
26. V. Evilevitch, W.A. Weber, W.D. Tap, M. Allen-Auerbach, K. Chow, and S.D. Nelson Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas Clin Cancer Res 14 2008 715 720
27. D.S. Hawkins, S.M. Schuetze, J.E. Butrynski, J.G. Rajendran, C.B. Vernon, and E.U. Conrad 3rd [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors J Clin Oncol 23 2005 8828 8834
28. J.R. Kroep, C.J. Van Groeningen, M.A. Cuesta, M.E. Craanen, O.S. Hoekstra, and E.F. Comans Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer;a comparison of different analytical methods Mol Imaging Biol 5 2003 337 346
29. T. Makino, Y. Doki, H. Miyata, T. Yasuda, M. Yamasaki, and Y. Fujiwara Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma Surgery 144 2008 793 802
30. F. Lordick, K. Ott, B.J. Krause, W.A. Weber, K. Becker, and H.J. Stein PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol 8 2007 797 805
31. TNM classification of malignant tumours 6th ed. 2002 Wiley New York
32. H. Akita, Y. Doki, H. Miyata, T. Hirao, M. Yano, and K. Takachi Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma J Surg Oncol 93 2006 401 409
33. H. Akita, Y. Doki, M. Yano, H. Miyata, I. Miyashiro, and H. Ohigashi Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis Dis Esophagus 22 2009 291 297
34. M. Yano, K. Takachi, Y. Doki, I. Miyashiro, K. Kishi, and S. Noura Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus Dis Esophagus 19 2006 158 163
35. Common Toxicity Criteria, version 2.0. Bethesda, MD: National Cancer Institute, 1998.
36. Y. Doki, O. Ishikawa, K. Takachi, I. Miyashiro, Y. Sasaki, and H. Ohigashi Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma World J Surg 29 2005 700 707
37. H. Miyata, M. Yano, Y. Doki, T. Yasuda, S. Yoshioka, and Y. Sugita A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes J Surg Oncol 93 2006 477 484
38. A.K. Paul, M. Tatsumi, I. Higuchi, H. Fukunaga, T. Yasuda, and T. Nishimura Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer Nucl Med Commun 24 2003 963 970
39. M. Tatsumi, K. Yutani, Y. Watanabe, S. Miyoshi, N. Tomiyama, and T. Johkoh Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET J Nucl Med 40 1999 566 573 (Pubitemid 29171797)
40. H. Fukunaga, M. Sekimoto, M. Tatsumi, M. Ikenaga, M. Ohue, and I. Seshimo Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer Int J Oncol 20 2002 691 695
41. W.A. Weber, S.I. Ziegler, R. Thodtmann, A.R. Hanauske, and M. Schwaiger Reproducibility of metabolic measurements in malignant tumors using FDG PET J Nucl Med 40 1999 1771 1777
42. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
43. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
44. J. Willis, G.S. Cooper, G. Isenberg, M.V. Sivak Jr., N. Levitan, and J. Clayman Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma Gastrointest Endosc 55 2002 655 661
45. A. Chak, M.I. Canto, and G.S. Cooper Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients Cancer 88 2000 1788 1795
46. W.A. Brown, J. Thomas, D. Gotley, B.H. Burmeister, K.H. Lim, and I. Martin Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy Br J Surg 91 2004 199 204
47. M. Westerterp, H.L. van Westreenen, J.B. Reitsma, O.S. Hoekstra, J. Stoker, and P. Fockens Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review Radiology 236 2005 841 851
48. S.G. Swisher, M. Maish, J.J. Erasmus, A.M. Correa, J.A. Ajani, and R. Bresalier Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer Ann Thorac Surg 78 2004 1152 1160
49. S.G. Swisher, J. Erasmus, M. Maish, A.M. Correa, H. Macapinlac, and J.A. Ajani 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma Cancer 101 2004 1776 1785
50. T.D. Luu, P. Gaur, S.D. Force, C.A. Staley, K.A. Mansour, and J.I. Miller Jr. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer Ann Thorac Surg 85 2008 1217 1223
51. J.D. Urschel, H. Vasan, and C.J. Blewett A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer Am J Surg 183 2002 274 279
52. E. Ancona, A. Ruol, S. Santi, S. Merigliano, V.C. Sileni, and H. Koussis Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone Cancer 91 2001 2165 2174
53. P.R. Rohatgi, S.G. Swisher, A.M. Correa, T.T. Wu, Z. Liao, and G.L. Walsh Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus Int J Gastrointest Cancer 36 2005 69 76
54. E. Heinmoller, B. Renke, and K. Beyser Pitfalls in diagnostic molecular pathology-significance of sampling error Virchows Arch 439 2001 504 511
55. D. Amadori, A. Volpi, R. Maltoni, O. Nanni, L. Amaducci, and A. Amadori Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study Breast Cancer Res Treat 43 1997 7 14
56. S. Costa, P. Terzano, D. Santini, C. Ceccarelli, A. Martoni, and B. Angelelli Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome Am J Clin Pathol 116 2001 729 737